Cargando…
Changes in serum albumin and other nutritional markers when using sucroferric oxyhydroxide as phosphate binder among hemodialysis patients: a historical cohort study
BACKGROUND: Elevated serum phosphorus concentrations are common among maintenance hemodialysis patients. Protein is a major source of dietary phosphate, but restriction of protein intake can result in hypoalbuminemia and protein-energy wasting. We hypothesized that sucroferric oxyhydroxide (SO), a p...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820926/ https://www.ncbi.nlm.nih.gov/pubmed/31664928 http://dx.doi.org/10.1186/s12882-019-1582-9 |
_version_ | 1783464045825753088 |
---|---|
author | Kalantar-Zadeh, Kamyar Ficociello, Linda H. Parameswaran, Vidhya Athienites, Nicolaos V. Mullon, Claudy Kossmann, Robert J. Coyne, Daniel W. |
author_facet | Kalantar-Zadeh, Kamyar Ficociello, Linda H. Parameswaran, Vidhya Athienites, Nicolaos V. Mullon, Claudy Kossmann, Robert J. Coyne, Daniel W. |
author_sort | Kalantar-Zadeh, Kamyar |
collection | PubMed |
description | BACKGROUND: Elevated serum phosphorus concentrations are common among maintenance hemodialysis patients. Protein is a major source of dietary phosphate, but restriction of protein intake can result in hypoalbuminemia and protein-energy wasting. We hypothesized that sucroferric oxyhydroxide (SO), a potent phosphate binder with a low pill burden, may reduce serum phosphorus levels in hemodialysis patients with hypoalbuminemia without adversely impacting albumin levels or dietary intake of protein. METHODS: We retrospectively examined de-identified data from 79 adult, in-center hemodialysis patients with baseline hypoalbuminemia (≤ 3.5 g/dL) switched to SO as part of routine clinical care for at least 1 year. Temporal changes (3-month intervals from baseline through Q4) in phosphate binder pill burden, serum phosphorous levels, nutritional markers, and equilibrated Kt/V were analyzed. Data from a matched reference group of non-hypoalbuminemic patients (N = 79) switched to SO were also examined. RESULTS: SO therapy was associated with a mean reduction of 45.7 and 45.1% in daily phosphate binder pill burden, and a mean reduction of 0.4 mg/dL and 0.51 mg/dL in serum phosphorus levels for the hypoalbuminemic and non-hypoalbuminemic patients, respectively. Hypoalbuminemic patients demonstrated significant increases in mean serum albumin levels from 3.50 mg/dL at baseline to 3.69, 3.74, 3.70, and 3.69 mg/dL during Q1 through Q4, respectively (P < 0.0001), whereas serum albumin levels remained unchanged in the non-hypoalbuminemic group. CONCLUSIONS: Both hypoalbuminemic and non-hypoalbuminemic patients switching to SO exhibited significant reductions in serum phosphorus concentrations and daily phosphate binder pill burden. Among hypoalbuminemic patients, the initiation of SO therapy was also associated with increases in serum albumin, suggesting therapy may have allowed patients to increase their dietary intake of protein. |
format | Online Article Text |
id | pubmed-6820926 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-68209262019-11-04 Changes in serum albumin and other nutritional markers when using sucroferric oxyhydroxide as phosphate binder among hemodialysis patients: a historical cohort study Kalantar-Zadeh, Kamyar Ficociello, Linda H. Parameswaran, Vidhya Athienites, Nicolaos V. Mullon, Claudy Kossmann, Robert J. Coyne, Daniel W. BMC Nephrol Research Article BACKGROUND: Elevated serum phosphorus concentrations are common among maintenance hemodialysis patients. Protein is a major source of dietary phosphate, but restriction of protein intake can result in hypoalbuminemia and protein-energy wasting. We hypothesized that sucroferric oxyhydroxide (SO), a potent phosphate binder with a low pill burden, may reduce serum phosphorus levels in hemodialysis patients with hypoalbuminemia without adversely impacting albumin levels or dietary intake of protein. METHODS: We retrospectively examined de-identified data from 79 adult, in-center hemodialysis patients with baseline hypoalbuminemia (≤ 3.5 g/dL) switched to SO as part of routine clinical care for at least 1 year. Temporal changes (3-month intervals from baseline through Q4) in phosphate binder pill burden, serum phosphorous levels, nutritional markers, and equilibrated Kt/V were analyzed. Data from a matched reference group of non-hypoalbuminemic patients (N = 79) switched to SO were also examined. RESULTS: SO therapy was associated with a mean reduction of 45.7 and 45.1% in daily phosphate binder pill burden, and a mean reduction of 0.4 mg/dL and 0.51 mg/dL in serum phosphorus levels for the hypoalbuminemic and non-hypoalbuminemic patients, respectively. Hypoalbuminemic patients demonstrated significant increases in mean serum albumin levels from 3.50 mg/dL at baseline to 3.69, 3.74, 3.70, and 3.69 mg/dL during Q1 through Q4, respectively (P < 0.0001), whereas serum albumin levels remained unchanged in the non-hypoalbuminemic group. CONCLUSIONS: Both hypoalbuminemic and non-hypoalbuminemic patients switching to SO exhibited significant reductions in serum phosphorus concentrations and daily phosphate binder pill burden. Among hypoalbuminemic patients, the initiation of SO therapy was also associated with increases in serum albumin, suggesting therapy may have allowed patients to increase their dietary intake of protein. BioMed Central 2019-10-29 /pmc/articles/PMC6820926/ /pubmed/31664928 http://dx.doi.org/10.1186/s12882-019-1582-9 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Kalantar-Zadeh, Kamyar Ficociello, Linda H. Parameswaran, Vidhya Athienites, Nicolaos V. Mullon, Claudy Kossmann, Robert J. Coyne, Daniel W. Changes in serum albumin and other nutritional markers when using sucroferric oxyhydroxide as phosphate binder among hemodialysis patients: a historical cohort study |
title | Changes in serum albumin and other nutritional markers when using sucroferric oxyhydroxide as phosphate binder among hemodialysis patients: a historical cohort study |
title_full | Changes in serum albumin and other nutritional markers when using sucroferric oxyhydroxide as phosphate binder among hemodialysis patients: a historical cohort study |
title_fullStr | Changes in serum albumin and other nutritional markers when using sucroferric oxyhydroxide as phosphate binder among hemodialysis patients: a historical cohort study |
title_full_unstemmed | Changes in serum albumin and other nutritional markers when using sucroferric oxyhydroxide as phosphate binder among hemodialysis patients: a historical cohort study |
title_short | Changes in serum albumin and other nutritional markers when using sucroferric oxyhydroxide as phosphate binder among hemodialysis patients: a historical cohort study |
title_sort | changes in serum albumin and other nutritional markers when using sucroferric oxyhydroxide as phosphate binder among hemodialysis patients: a historical cohort study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820926/ https://www.ncbi.nlm.nih.gov/pubmed/31664928 http://dx.doi.org/10.1186/s12882-019-1582-9 |
work_keys_str_mv | AT kalantarzadehkamyar changesinserumalbuminandothernutritionalmarkerswhenusingsucroferricoxyhydroxideasphosphatebinderamonghemodialysispatientsahistoricalcohortstudy AT ficociellolindah changesinserumalbuminandothernutritionalmarkerswhenusingsucroferricoxyhydroxideasphosphatebinderamonghemodialysispatientsahistoricalcohortstudy AT parameswaranvidhya changesinserumalbuminandothernutritionalmarkerswhenusingsucroferricoxyhydroxideasphosphatebinderamonghemodialysispatientsahistoricalcohortstudy AT athienitesnicolaosv changesinserumalbuminandothernutritionalmarkerswhenusingsucroferricoxyhydroxideasphosphatebinderamonghemodialysispatientsahistoricalcohortstudy AT mullonclaudy changesinserumalbuminandothernutritionalmarkerswhenusingsucroferricoxyhydroxideasphosphatebinderamonghemodialysispatientsahistoricalcohortstudy AT kossmannrobertj changesinserumalbuminandothernutritionalmarkerswhenusingsucroferricoxyhydroxideasphosphatebinderamonghemodialysispatientsahistoricalcohortstudy AT coynedanielw changesinserumalbuminandothernutritionalmarkerswhenusingsucroferricoxyhydroxideasphosphatebinderamonghemodialysispatientsahistoricalcohortstudy |